Medical science has achieved a significant victory in the battle against lung cancer, marking a milestone in the field. The New England Journal of Medicine has reported a major breakthrough, shedding light on the extraordinary efficacy of the medication Osimertinib, commercially known as Tagrisso. According to a comprehensive report by Fox News Digital, this medication has proven to be a game-changer, demonstrating a substantial reduction in the five-year risk of recurrent cancer by an impressive 73% and decreasing the risk of death by an equally remarkable 51%.
Dr. Faiz Y. Bhora, the Chief of Thoracic Surgery and Central Region Chair of Surgery at Hackensack Meridian Health in New Jersey, expressed his enthusiasm about the groundbreaking results. In an exclusive interaction with Fox News Digital, Dr. Bhora emphasized the unprecedented progress, noting that oncologists were content with a 5% or 10% improvement, and now, the focus is on an exceptional advancement exceeding 50% in terms of survival.
Dr. Bhora shared his personal experience, revealing that he has recommended the medication to numerous lung cancer patients, witnessing positive outcomes. "We're truly in the era of personalized medicine. We now have a lot of targeted therapies that work well for patients who have mutations in their tumours," added Dr Bhora.
The effectiveness of Tagrisso extends to patients with a specific genetic mutation called EGFRm who have undergone surgery. Dr Bhora explained that the pill plays a crucial role in preventing recurrence post-tumour removal for individuals with this genetic marker.
Dr. Bhora sheds light on a common misconception about lung cancer, dispelling the notion that it solely affects smokers. Lung cancer is not confined to a specific demographic; over 30% of individuals diagnosed have never smoked, with a notable number being women. This revelation reshapes our understanding of the disease, emphasizing the need for broader awareness and targeted interventions.
As the medical community celebrates this remarkable achievement, the era of personalized medicine opens new doors for targeted therapies, offering hope to a broader spectrum of lung cancer patients. The impact of Osimertinib, with its brand name Tagrisso, resonates as a ray of progress in the relentless pursuit of effective cancer treatments.